Form 4: SI-BONE Director Thomas A. West Receives 8,675 Restricted Stock Units

SI-BONE, Inc. Director Thomas A. West was granted 8,675 restricted stock units, increasing his total beneficial ownership to 26,990 shares, as disclosed in a recent SEC Form 4 filing.

Summary

• Thomas A. West, a Director of SI-BONE, Inc. (SIBN), was granted 8,675 restricted stock units (RSUs) on June 5, 2025.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• These RSUs will vest 100% upon the earlier of the next annual general meeting of stockholders or one year from the Vesting Commencement Date, contingent on Mr. West's continuous service as a member of the Company's Board of Directors.
• Following this transaction, Mr. West's total beneficial ownership in SI-BONE, Inc. stands at 26,990 shares, which includes 23,937 shares issuable from the settlement of restricted stock units.
• The filing also includes a Power of Attorney dated June 7, 2024, authorizing specific individuals to file Section 16 reports on behalf of Mr. West.

Sentiment

Score: 7

Explanation: The grant of equity compensation to a director is a positive event as it aligns interests and incentivizes long-term commitment, reflecting standard corporate governance practices. No negative information was disclosed.

Positives

• The grant of 8,675 restricted stock units to a director aligns his interests with those of shareholders, promoting long-term value creation.
• The vesting schedule, contingent on continuous service, incentivizes the director's ongoing commitment to the company.
• Increased beneficial ownership by a director can signal confidence in the company's future prospects.

Risks

• The vesting of the restricted stock units is contingent on the director's continuous service, meaning the shares are not guaranteed if service ceases before the vesting conditions are met.

Future Outlook

The restricted stock units granted to Director Thomas A. West are scheduled to vest 100% upon the earlier of the next annual general meeting of stockholders or one year from the Vesting Commencement Date, provided his continuous service as a Board member. This indicates a future commitment and expected tenure for the director.

Industry Context

This filing is a routine disclosure of director equity compensation, common across publicly traded companies. It reflects standard practices for aligning executive and director incentives with shareholder value through equity grants, particularly in the medical device sector.

Comparison to Industry Standards

• The grant of restricted stock units (RSUs) at a $0.00 exercise price is a standard form of equity compensation for directors in the medical device or broader healthcare industry, similar to practices at companies like Medtronic or Stryker for their non-employee directors.
• The vesting schedule, tied to continued service and annual meetings, is also a common mechanism to ensure long-term commitment, comparable to governance practices seen in other S&P 500 companies.

Corporate Governance

Related Party Transactions

• The grant of 8,675 restricted stock units to Thomas A. West, a director of SI-BONE, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with those of shareholders, potentially leading to decisions that enhance long-term shareholder value.

Next Steps

• The restricted stock units granted to Thomas A. West are expected to vest 100% upon the earlier of the next annual general meeting of stockholders or one year from the Vesting Commencement Date.

Key Dates

Recommendation

Keywords

SI-BONE, SIBN, Thomas A. West, Restricted Stock Units, RSU, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Corporate Governance